This site is intended for healthcare professionals only

COVID-19: NHS patients to receive get life-saving treatment

Written by: | Published:

The drug reduces hospital stay by 5 days The drug reduces hospital stay by 5 days

Thousands more NHS patients who are hospitalised due to COVID-19 will be able to receive tocilizumab, the Government has announced.

Clinical trials show that the drug, originally used to treat arthritis reduces the risk of death by 14% and reduced the time spent in hospital by 5 days for patients on oxygen on top of benefits from dexamethasone. According to the Government, the roll-out of this treatment could also contribute significantly towards reducing pressures on hospitals over the coming weeks and months.

Read more: Over 4 million people receive first dose of COVID-19 vaccine

‘These results present another important advance in our fight against COVID-19 and are good news for patients and clinicians around the world – it’s a combination of both effective therapeutics and vaccines that will mean an end to this pandemic,’ said Deputy Chief Medical Officer Professor Jonathan Van-Tam.

‘The data published today mean many more patients in hospital with COVID-19 will have access to a proven treatment, speeding up their recovery and reducing the risk of mortality significantly.’

Read more: COVID-19: New Oxford vaccine rolled out to general practice services

Scientists discovered the drug was effective during the RECOVERY clinical trial, funded by the UK government through the National Institute for Health Research and UK Research and Innovation. Last month, the international clinical trial REMAP-CAP, also funded by the government, found that tocilizumab and sarilumab reduced the risk of death for patients when administered within 24 hours of entering intensive care.

‘Throughout the pandemic where the NHS leads, the world has followed – from vaccinating the first patients outside of clinical trials to helping get dexamethasone into frontline care, and now to driving forward research on another breakthrough treatment,’ said Professor Stephen Powis, NHS national medical director.

‘I am immensely proud that the NHS is delivering another breakthrough treatment that will significantly increase the chances of survival for COVID patients being treated in England’s hospitals.’

What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.



Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code

Most read articles from Practice Nursing Journal

Practice Nursing Journal latest issue and most read articles.

Click here to read a selection of free to access articles from Practice Nursing Journal


Sign up to the newsletter


Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.


Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.


Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team


Find out how to contribute to Independent Nurse here.